Pre-Test Exploring Current and Emerging Biosimilars for IBD Management Pre-Test According to a recent report, the availability and use of biosimilar medicines has the potential to reduce drug costs by ________ over the next 5 years. $10-121 Million $38-181 Million $10-121 Billion $38-181 Billion Unsure The adalimumab biosimilar, adalimumab-aacf, was approved for the treatment of IBD, in part, based on ________ that demonstrated no clinically significant difference between the biologic and biosimilar. Extrapolation of Data Interchangeability Non-Superiority Trials Totality of Evidence Unsure _________ is the first IBD-indicated FDA-approved interchangeable biosimilar product for its reference product. Adalimumab-aacf Adalimumab-adbm Infliximab-abda Infliximab-dyyb Unsure Biosimilars are positioned the same as the reference product in the clinical care paradigm and switching may be driven by: Cost and accessibility considerations Development of anti-drug antibodies Intolerable side-effects No response on the corresponding biologic Unsure How confident are you in your ability to appropriately evaluate and utilize biosimilars in clinical practice for the treatment of IBD? Very confident Confident Somewhat confident Not very confident Not at all confident
